82.475 USD
+1.07 (+1.32%)
TARS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of TARS is average, but there are quite some concerns on its profitability. TARS shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TARS had negative earnings in the past year.
TARS had a negative operating cash flow in the past year.
TARS had negative earnings in each of the past 5 years.
TARS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of TARS (-15.18%) is better than 62.50% of its industry peers.
TARS's Return On Equity of -24.22% is fine compared to the rest of the industry. TARS outperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROIC | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 93.26%, TARS belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
In the last couple of years the Gross Margin of TARS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TARS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
TARS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TARS has more shares outstanding
Compared to 1 year ago, TARS has a worse debt to assets ratio.
2.2 Solvency
TARS has an Altman-Z score of 10.31. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
TARS's Altman-Z score of 10.31 is amongst the best of the industry. TARS outperforms 81.77% of its industry peers.
TARS has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.22, TARS perfoms like the industry average, outperforming 44.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.31 |
ROIC/WACCN/A
WACC9.49%
2.3 Liquidity
TARS has a Current Ratio of 4.29. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
TARS's Current ratio of 4.29 is fine compared to the rest of the industry. TARS outperforms 61.46% of its industry peers.
TARS has a Quick Ratio of 4.25. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
TARS has a Quick ratio of 4.25. This is in the better half of the industry: TARS outperforms 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 |
3. Growth
3.1 Past
TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.98%, which is quite impressive.
The Revenue has grown by 182.44% in the past year. This is a very strong growth!
The Revenue has been growing by 47.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
3.2 Future
TARS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.25% yearly.
The Revenue is expected to grow by 46.55% on average over the next years. This is a very strong growth
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y52.04%
EPS Next 5Y36.25%
Revenue Next Year153.71%
Revenue Next 2Y97.09%
Revenue Next 3Y71.47%
Revenue Next 5Y46.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 46.25, the valuation of TARS can be described as expensive.
TARS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TARS is cheaper than 69.79% of the companies in the same industry.
TARS is valuated expensively when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 46.25 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TARS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TARS's earnings are expected to grow with 52.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.48%
EPS Next 3Y52.04%
5. Dividend
5.1 Amount
No dividends for TARS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TARS (12/22/2025, 11:53:42 AM)
82.475
+1.07 (+1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.99%
Inst Owner Change-6.9%
Ins Owners3.25%
Ins Owner Change-1.11%
Market Cap3.50B
Revenue(TTM)366.10M
Net Income(TTM)-81.16M
Analysts86.67
Price Target88.63 (7.46%)
Short Float %17.93%
Short Ratio14.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.85%
Min EPS beat(2)-17.77%
Max EPS beat(2)16.07%
EPS beat(4)3
Avg EPS beat(4)8.3%
Min EPS beat(4)-17.77%
Max EPS beat(4)20.78%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)10
Avg EPS beat(12)11.89%
EPS beat(16)13
Avg EPS beat(16)13.53%
Revenue beat(2)2
Avg Revenue beat(2)3.09%
Min Revenue beat(2)0.99%
Max Revenue beat(2)5.19%
Revenue beat(4)4
Avg Revenue beat(4)5.95%
Min Revenue beat(4)0.99%
Max Revenue beat(4)11.62%
Revenue beat(8)8
Avg Revenue beat(8)30.02%
Revenue beat(12)9
Avg Revenue beat(12)39.62%
Revenue beat(16)10
Avg Revenue beat(16)13.76%
PT rev (1m)10.59%
PT rev (3m)17.87%
EPS NQ rev (1m)43.83%
EPS NQ rev (3m)-9.95%
EPS NY rev (1m)6.48%
EPS NY rev (3m)-6.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.2%
Revenue NY rev (1m)3.25%
Revenue NY rev (3m)4.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 46.25 | ||
| P/S | 9.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.45 | ||
| P/tB | 10.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.02
EYN/A
EPS(NY)1.78
Fwd EY2.16%
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS8.62
BVpS7.89
TBVpS7.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% | ||
| FCFM | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 474.96% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 | ||
| Altman-Z | 10.31 |
F-Score5
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)439.33%
Cap/Depr(5y)393.66%
Cap/Sales(3y)12.37%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y52.04%
EPS Next 5Y36.25%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
Revenue Next Year153.71%
Revenue Next 2Y97.09%
Revenue Next 3Y71.47%
Revenue Next 5Y46.55%
EBIT growth 1Y37.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.9%
EBIT Next 3Y61.22%
EBIT Next 5Y49.54%
FCF growth 1Y33.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.39%
OCF growth 3YN/A
OCF growth 5YN/A
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you provide the ChartMill fundamental rating for TARSUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to TARS.
What is the valuation status of TARSUS PHARMACEUTICALS INC (TARS) stock?
ChartMill assigns a valuation rating of 2 / 10 to TARSUS PHARMACEUTICALS INC (TARS). This can be considered as Overvalued.
Can you provide the profitability details for TARSUS PHARMACEUTICALS INC?
TARSUS PHARMACEUTICALS INC (TARS) has a profitability rating of 2 / 10.
Can you provide the financial health for TARS stock?
The financial health rating of TARSUS PHARMACEUTICALS INC (TARS) is 5 / 10.
Can you provide the expected EPS growth for TARS stock?
The Earnings per Share (EPS) of TARSUS PHARMACEUTICALS INC (TARS) is expected to grow by 51.69% in the next year.